Executive Vice President, Research & Development,
United States of America
Narendra Lalwani is Executive Vice President, Research and Development, and Chief Operating Officer. Prior to joining Esperion, Narendra was Chief Scientific Officer at Cerenis Therapeutics from 2007 to 2014 where he led R&D activities for the company. Previously, Narendra was Vice President of Drug Safety at the original Esperion until its acquisition by Pfizer. Prior to Esperion, Narendra held various positions of increasing responsibility in the Department of Pathology and Experimental Toxicology at Warner-Lambert/Parke-Davis. Narendra is a Fellow of American Heart Association (FAHA) and a diplomate of the American board of Toxicology (DABT). Narendra earned a PhD in Biophysics from the University of Bombay (India) and an MBA from the University of Michigan, Ross School of Business.
Drug Safety, Pathology ,Toxicology